101 
Market Cap
As of July 16, 2010: $11,359,000.00
Stock Chart
Prima Biomed - 30 Day Poll
Recent BLOGS About Prima Biomed Add New
There are no blogs to display.
Latest Company News
|
Prima BioMed Limited Appoints Mr. Albert Wong As Interim Chairman
Reuters Key Development - Jul 23, 2010 |
|
Prima BioMed gets European product designation
Australian Life Scientist - Jun 3, 2010 Prima BioMed announced today that its CVac ovarian cancer therapy vaccine has been granted Orphan Medicinal Product Designation by the European Medicines Agency ( EMA ). The company said that the ...
|
|
Prima BioMed Limited Granted European Orphan Drug Designation For CVac
Reuters Key Development - Jun 3, 2010 |
|
Prima BioMed Limited Enters Partnership With Fraunhofer Institute For Production Of CVac In Europe
Reuters Key Development - May 26, 2010 |
|
Prima BioMed Limited Obtains SME Status In Europe And Submits Orphan Product Designation Application For Cvac To European Medicines Agency
Reuters Key Development - Mar 4, 2010 |
Website
Videos related to Prima Biomed
Company Profile
The company has 3 programs in place.
The lead program, CVacTM has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer. The CVac product consists of an adjuvant, attached to a tumour cell surface protein. The treatment is patient-specific and delivered to patients via dendritic cell therapy i.e.patient’s dendritic cells are isolated from their blood & surface protein is mixed with the cells to introduce the protein so it is expressed on the surface of the cells. Cells are then re-introduced to the patient. A successful phase I trial was completed which examined the safety of the product in patients with adenocarcinomas. All patients produced an immune response to the product. The phase IIa clinical trial to determine clinical activity in ovarian cancer announced evidence of clinical activity in response to CVacTM therapy. CVacTM demonstrated a positive clinical response or stabilisation of disease in four of the twenty-one patients.
The second program is focussing on the identification of an antibody to tumour cell target, cripto-1. This program has been partnered with Medarex Inc. (see our USA sister website).
The third is focussing on the development of an adjuvant in Cancer & infectious disease vaccines. It could be coupled to a variety of antigens from viruses, bacteria or parasites to induce a protective immune responses (antibody and T cells). Biological proof of principal has been achieved and early product development has commenced.
Of Note:
Dendreon is a similar company in terms of technological apporach and has done well so far re prostate cancer - see our sister USA website
Upcoming Events:
- Prima submitted an IND with the FDA in July 2009 for Dendritic cell therapy
- Multicentre Phase IIb Ovarian cancer trial to commence – Q4 2009
The lead program, CVacTM has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer. The CVac product consists of an adjuvant, attached to a tumour cell surface protein. The treatment is patient-specific and delivered to patients via dendritic cell therapy i.e.patient’s dendritic cells are isolated from their blood & surface protein is mixed with the cells to introduce the protein so it is expressed on the surface of the cells. Cells are then re-introduced to the patient. A successful phase I trial was completed which examined the safety of the product in patients with adenocarcinomas. All patients produced an immune response to the product. The phase IIa clinical trial to determine clinical activity in ovarian cancer announced evidence of clinical activity in response to CVacTM therapy. CVacTM demonstrated a positive clinical response or stabilisation of disease in four of the twenty-one patients.
The second program is focussing on the identification of an antibody to tumour cell target, cripto-1. This program has been partnered with Medarex Inc. (see our USA sister website).
The third is focussing on the development of an adjuvant in Cancer & infectious disease vaccines. It could be coupled to a variety of antigens from viruses, bacteria or parasites to induce a protective immune responses (antibody and T cells). Biological proof of principal has been achieved and early product development has commenced.
Of Note:
Dendreon is a similar company in terms of technological apporach and has done well so far re prostate cancer - see our sister USA website
Upcoming Events:
- Prima submitted an IND with the FDA in July 2009 for Dendritic cell therapy
- Multicentre Phase IIb Ovarian cancer trial to commence – Q4 2009
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use